KANSAI MEDICAL UNIVERSITY

NEXT Oncology Expands Phase I Cancer Trial Network to Japan Through Kansai Medical University Partnership

- NEXT Oncology has formed a strategic partnership with Kansai Medical University in Osaka, Japan, expanding its Phase I cancer trial network to Asia under the direction of Dr. Toshio Shimizu. - The collaboration brings NEXT Oncology's global network to nine locations across four continents, treating more than 1,000 patients annually and cementing its position as one of the world's largest Phase I clinical trial organizations. - Kansai Medical University Hospital currently operates more than twenty first-in-human Phase I oncology trials and houses Japan's only Near InfraRed Photo-ImmunoTherapy Research Institute. - The partnership aims to provide Japanese cancer patients access to breakthrough experimental therapies while contributing to global oncology research and drug development efforts.